873 results on '"Vogelmeier, Claus F."'
Search Results
2. Midregional Proatrial Natriuretic Peptide (MRproANP) is associated with vertebral fractures and low bone density in patients with chronic obstructive pulmonary disease (COPD)
3. Effects of triple therapy on disease burden in patients of GOLD groups C and D: results from the observational COPD cohort COSYCONET
4. GOLD COPD DOCUMENT 2023: a brief update for practicing cardiologists
5. Genetisch bedingte Lungenerkrankungen
6. Gold 2023: Highlights for primary care
7. In ‘real world’ patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations
8. Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD
9. EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
10. A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”
11. Impact of COPD on mortality: An 8-year observational retrospective healthcare claims database cohort study
12. Potential systemic effects of acquired CFTR dysfunction in COPD
13. Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities
14. COPD and multimorbidity: recognising and addressing a syndemic occurrence
15. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis
16. Diagnostic Performance of a Machine Learning Algorithm (Asthma/Chronic Obstructive Pulmonary Disease [COPD] Differentiation Classification) Tool Versus Primary Care Physicians and Pulmonologists in Asthma, COPD, and Asthma/COPD Overlap
17. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
18. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
19. Genetic lung diseases
20. Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study
21. Lungenerkrankung nach Senfgasexposition
22. Association of coronary artery calcification with clinical and physiological characteristics in patients with COPD: Results from COSYCONET
23. A scoping review of mHealth monitoring of pediatric bronchial asthma before and during COVID-19 pandemic
24. Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD
25. Quantification of pulmonary perfusion abnormalities using DCE-MRI in COPD: comparison with quantitative CT and pulmonary function
26. Sex-specific associations of comorbidome and pulmorbidome with mortality in chronic obstructive pulmonary disease: results from COSYCONET
27. Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment
28. IgE is associated with exacerbations and lung function decline in COPD
29. Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ study
30. Cardiovascular predictors of mortality and exacerbations in patients with COPD
31. Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study.
32. Differential Impact of Low Fat-Free Mass in People With COPD Based on BMI Classifications: Results From the COPD and Systemic Consequences-Comorbidities Network
33. Elucidating the risk of cardiopulmonary consequences of an exacerbation of COPD: results of the EXACOS-CV study in Germany
34. Implementing remote monitoring for COVID-19 patients in primary care
35. Early Diagnosis and Treatment of COPD: The Costs and Benefits of Case-Finding
36. COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort
37. The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
38. Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial
39. Correction to: Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis
40. Artificial Intelligence/Machine Learning in Respiratory Medicine and Potential Role in Asthma and COPD Diagnosis
41. Chronisch-obstruktive Lungenerkrankung 2021 – die richtige Therapie für den richtigen Patienten
42. Measurement of urinary Dickkopf-3 uncovered silent progressive kidney injury in patients with chronic obstructive pulmonary disease
43. COPDCompEx: A novel composite endpoint for COPD exacerbations to enable faster clinical development
44. Expiratory Venous Volume and Arterial Tortuosity are Associated with Disease Severity and Mortality Risk in Patients with COPD: Results from COSYCONET.
45. Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET
46. Utilization and determinants of use of non-pharmacological interventions in COPD: Results of the COSYCONET cohort
47. Goals of COPD treatment: Focus on symptoms and exacerbations
48. Impact of COPD on mortality: An 8-year observational retrospective healthcare claims database cohort study
49. Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial
50. Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.